Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP

Autor:	Shi Wei, Haiyan Dong, Shanli Zhu, Jun Chen, Li Mingyang, Lifang Zhang, Jia Yang, Qi Wang
Rok vydání:	2021
Předmět:	Porins Chlamydia trachomatis urologic and male genital diseases medicine.disease_cause Applied Microbiology and Biotechnology Epitope Epitopes 03 medical and health sciences 0302 clinical medicine Antigen Staphylococcus aureus protein A medicine Humans Biotechnologically Relevant Enzymes and Proteins Peptide library Affibody molecules 030304 developmental biology 0303 health sciences Chlamydia biology Chemistry General Medicine Chlamydia Infections bacterial infections and mycoses medicine.disease Antibodies Bacterial Virology female genital diseases and pregnancy complications 030220 oncology & carcinogenesis biology.protein bacteria MOMP Affibody molecule Antibody Bacterial Outer Membrane Proteins Biotechnology
Zdroj:	Applied Microbiology and Biotechnology
ISSN:	1432-0614 0175-7598
Popis:	Abstract Chlamydia trachomatis (C. trachomatis) is the leading cause of preventable blindness worldwide and the most prevalent cause of bacterial sexually transmitted diseases. At present, there is no available vaccine, and recurrences after antibiotics treatment are substantial problems. Major outer membrane protein (MOMP) accounts for 60% of the outer mass of C. trachomatis, functioning as trimeric porin, and it is highly antigenic. Therefore, MOMP is the most promising candidate for vaccine developing and target therapy of Chlamydia. Affibody, a new class of affinity ligands derived from the Z-domain in the binding region of Staphylococcus aureus protein A, has been the focus of researchers as a viable alternative to antibodies. In this study, the MOMP-targeted affibody molecule (ZMOMP:461) was screened by phage-displayed peptide library. Further, the affinity and specificity were characterized by surface plasmon resonance (SPR) and Western blot. Immunofluorescence assay (IFA) indicated that the MOMP-binding affibody could recognize native MOMP in HeLa229 cells infected C. trachomatis. Immunoprecipitation assay confirmed further that ZMOMP:461 molecule specifically recognizes the epitope on relaxed trimer MOMP. Our findings provide strong evidence that affibody molecule (ZMOMP:461) serves as substitute for MOMP antibody for biological applications and has a great potential for delivering drugs for target therapy. Key points • We screened a novel affibody molecule ZMOMP:461 targeting Chlamydia trachomatis MOMP. • ZMOMP:461 recognizes the recombinant and native MOMP with high affinity and specificity. • ZMOMP:461 could be internalized into live target cells.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9583b838b94464efa13cb2f4eb69a0b8 https://doi.org/10.1007/s00253-021-11128-x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.